Soleno Therapeutics, Inc. (SLNO)

Market Cap	2.42B
Revenue (ttm)	98.68M
Net Income (ttm)	-78.45M
Shares Out	53.71M
EPS (ttm)	-1.62
PE Ratio	n/a
Forward PE	13.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,309,577
Open	44.55
Previous Close	44.95
Day's Range	44.20 - 46.97
52-Week Range	41.50 - 90.32
Beta	-3.19
Analysts	Strong Buy
Price Target	110.90 (+145.84%)
Earnings Date	Nov 4, 2025

About SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwoo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 13, 2014
• Employees: 92
• Stock Exchange: NASDAQ
• Ticker Symbol: SLNO
• Website: https://soleno.life

Analyst Summary

According to 10 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price target is $110.9, which is an increase of 145.84% from the latest price.

Price Target

$110.9

(145.84% upside)

Analyst Consensus: Strong Buy